Evidence map›Paper›PMID 42661166›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Exploration of novel hydroxamic acid-based candidates integrating chalcone scaffold cap as multitarget HDAC inhibitors: design, anti-prostatic cancer assessment,

Aya I Abd El-Hameed, Ibrahim M Salem, Rasha M Allam, Mariem M Arafat, Hossameldin A Aziz, Zuhier A Awan, Tarek S Ibrahim, Omar Alshazly, Eman A M Beshr, Stefan Bräse and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aya I Abd El-HameedDepatment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, Egypt.
Ibrahim M SalemDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sphinx University, New Assuit City, Assiut, Egypt.
Rasha M AllamPharmacology Department, Medical and Clinical Research Institute, National Research Centre, Dokki, Cairo, Egypt.
Mariem M ArafatCell Culture Unit, Life Science Division, Nawah-Scientific Inc, Cairo, Egypt.
Hossameldin A AzizDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, New Valley University, New Valley, Egypt.
Zuhier A AwanDepartment of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Tarek S IbrahimDepartment of Organic Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Omar AlshazlyDepatment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, Egypt.
Eman A M BeshrDepartment of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
Stefan BräseInstitute for Biological and Chemical System, Karlsruhe Institute of Technology, Karlsruhe, Germany.
Mamdouh F A MohamedDepatment of Pharmaceutical Chemistry, Faculty of Pharmacy, Sohag University, Sohag, Egypt.ORCID 0000-0002-7046-1799

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two novel series of hydroxamic acid hybrids were designed and synthesised as anticancer agents

Indexed as

Antineoplastic AgentsChalconeDrug DesignHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsMolecular Docking SimulationMolecular Dynamics SimulationProstatic NeoplasmsApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMaleAntineoplastic AgentsChalconeHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsChalconeHDAC inhibitorsosteosarcomaprostate cancertargeted anticancer

Identifiers

PMID42661166
PMCPMC13523115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.